Class Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA)

Simply Wall St.04-18

In April 2026, law firms Kessler Topaz Meltzer & Check and Bernstein Litowitz Berger & Grossmann announced that a securities case against Natera and certain officers and directors was certified as a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2628785400?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-18 01:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628785400","market":"us","top_or_hot":-1,"title":"Class Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA)","media":"Simply Wall St.","content":"<div>\n<p>In April 2026, law firms Kessler Topaz Meltzer & Check and Bernstein Litowitz Berger & Grossmann announced that a securities case against Natera and certain officers and directors was certified as a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/class-action-certification-and-clarity-mrd-data-might-change\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Class Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClass Action Certification and CLARITY MRD Data Might Change The Case For Investing In Natera (NTRA)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-18 01:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/class-action-certification-and-clarity-mrd-data-might-change><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In April 2026, law firms Kessler Topaz Meltzer & Check and Bernstein Litowitz Berger & Grossmann announced that a securities case against Natera and certain officers and directors was certified as a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/class-action-certification-and-clarity-mrd-data-might-change\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1064131342.USD","symbol_name":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/class-action-certification-and-clarity-mrd-data-might-change","article_id":"2628785400","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/class-action-certification-and-clarity-mrd-data-might-change","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2628785400","pubTimestamp":1776445843,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In April 2026, law firms Kessler Topaz Meltzer & Check and Bernstein Litowitz Berger & Grossmann announced that a securities case against Natera and certain officers and directors was certified as a class action, while plaintiffs sought voluntary dismissal without prejudice of specific Securities Act claims against the underwriters. \nNatera was also highlighted by Allogene Therapeutics after interim ALPHA3 trial data in large B‑cell lymphoma used Natera’s CLARITY MRD assay to show meaningful...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4139":"生物科技","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","NTRA":"Natera, Inc.","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC"},"translate_title":"集体诉讼认证和清晰的MRD数据可能会改变投资Natera(NTRA)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5},"content_text":"In April 2026, law firms Kessler Topaz Meltzer & Check and Bernstein Litowitz Berger & Grossmann announced that a securities case against Natera and certain officers and directors was certified as a class action, while plaintiffs sought voluntary dismissal without prejudice of specific Securities Act claims against the underwriters.  Natera was also highlighted by Allogene Therapeutics after interim ALPHA3 trial data in large B‑cell lymphoma used Natera’s CLARITY MRD assay to show meaningful minimal residual disease clearance, underscoring the assay’s potential clinical value in oncology decision-making.  With Natera’s CLARITY MRD assay featuring in Allogene’s lymphoma trial, we’ll examine how this clinical validation shapes the company’s investment narrative.  Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.AdvertisementNatera Investment Narrative RecapTo own Natera, you need to believe its MRD and broader genomic testing portfolio can convert growing clinical adoption into improving economics over time, despite ongoing losses and legal complexity. The newly certified securities class action adds legal overhang, while ALPHA3 data using Natera’s CLARITY MRD assay supports the clinical relevance that underpins near term catalysts around adoption, partnerships, and reimbursement. For now, the trial readout appears more impactful than the class action for the business outlook. The ALPHA3 interim results, where 58.3% of MRD positive patients on Allogene’s cema cel achieved MRD clearance using Natera’s CLARITY assay, are particularly relevant. They build on Natera’s broader MRD story, including its February 2026 PMA submission for Signatera CDx in muscle invasive bladder cancer, which could be a key regulatory catalyst if approved. Together, these data points reinforce how clinical validation may influence Natera’s ability to convert testing volume into more durable revenue. Yet, despite this progress, investors should be aware that growing legal and regulatory pressures could still... Read the full narrative on Natera (it's free!)Natera's narrative projects $3.8 billion revenue and $129.1 million earnings by 2029. This requires 18.0% yearly revenue growth and a $337.3 million earnings increase from -$208.2 million today.Uncover how Natera's forecasts yield a $259.11 fair value, a 32% upside to its current price.Exploring Other PerspectivesNTRA 1-Year Stock Price Chart While consensus focuses on steady growth, the most optimistic analysts were assuming revenue near US$3.4 billion and about US$623 million in earnings by 2028, so this new legal overhang and reimbursement risk could push views on Natera’s upside in very different directions.Explore 5 other fair value estimates on Natera - why the stock might be worth just $208.44!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Natera research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.Searching For A Fresh Perspective?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Outshine the giants: these 19 early-stage AI stocks could fund your retirement.We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628785400","isCrawlerRequest":true}